{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:16:02Z","timestamp":1765178162497,"version":"build-2065373602"},"reference-count":68,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia\/Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior (FCT\/MCTES, Portugal)","doi-asserted-by":"publisher","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Associated Laboratory LS4FUTURE","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"]}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CICS-UBI (Health Sciences Research Centre\u2014University of Beira Interior)","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","UIDB\/04612\/2020","UIDP\/04612\/2020","LA\/P\/0087\/2020","AAC 01\/SAICT\/2016","SFRH\/BPD\/111100\/2015","POVT-0439-FEDER-00001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Ovarian cancer is the major cause of death from gynecological cancer and the third most common gynecological malignancy worldwide. Despite a slight improvement in the overall survival of ovarian carcinoma patients in recent decades, the cure rate has not improved. This is mainly due to late diagnosis and resistance to therapy. It is therefore urgent to develop effective methods for early detection and prognosis. We hypothesized that, besides being able to distinguish serum samples of patients with ovarian cancer from those of patients with benign ovarian tumors, 1H-NMR metabolomics analysis might be able to predict the malignant potential of tumors. For this, serum 1H-NMR metabolomics analyses were performed, including patients with malignant, benign and borderline ovarian tumors. The serum metabolic profiles were analyzed by multivariate statistical analysis, including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) methods. A metabolic profile associated with ovarian malignant tumors was defined, in which lactate, 3-hydroxybutyrate and acetone were increased and acetate, histidine, valine and methanol were decreased. Our data support the use of 1H-NMR metabolomics analysis as a screening method for ovarian cancer detection and might be useful for predicting the malignant potential of borderline tumors.<\/jats:p>","DOI":"10.3390\/metabo13090989","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:24:53Z","timestamp":1693560293000},"page":"989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-7753","authenticated-orcid":false,"given":"Sofia C.","family":"Nunes","sequence":"first","affiliation":[{"name":"iNOVA4Health, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"given":"Joana","family":"Sousa","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier (ITQB NOVA), Avenida da Rep\u00fablica (EAN), 2780-157 Oeiras, Portugal"}]},{"given":"Fernanda","family":"Silva","sequence":"additional","affiliation":[{"name":"iNOVA4Health, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"given":"Margarida","family":"Silveira","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"given":"Ant\u00f3nio","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-5907","authenticated-orcid":false,"given":"Jacinta","family":"Serpa","sequence":"additional","affiliation":[{"name":"iNOVA4Health, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-2262","authenticated-orcid":false,"given":"Ana","family":"F\u00e9lix","sequence":"additional","affiliation":[{"name":"iNOVA4Health, NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-3552","authenticated-orcid":false,"given":"Lu\u00eds G.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier (ITQB NOVA), Avenida da Rep\u00fablica (EAN), 2780-157 Oeiras, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: Recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14737140.2017.1299575","article-title":"Epidemiology and treatment patterns of epithelial ovarian cancer","volume":"17","author":"Jessmon","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: New opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","article-title":"Ovarian borderline tumors in the 2014 WHO classification: Evolving concepts and diagnostic criteria","volume":"470","author":"Hauptmann","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/AOG.0000000000000854","article-title":"Trends in relative survival for ovarian cancer from 1975 to 2011","volume":"125","author":"Wright","year":"2015","journal-title":"Obs. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S0025727300000521","article-title":"From the \u201cSilent Killer\u201d to the \u201cWhispering Disease\u201d: Ovarian Cancer and the Uses of Metaphor","volume":"53","author":"Jasen","year":"2009","journal-title":"Med. Hist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1634\/theoncologist.2012-0139","article-title":"Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors","volume":"17","author":"Fischerova","year":"2012","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17425255.2016.1238460","article-title":"Metabolomic profiling for early cancer detection: Current status and future prospects","volume":"12","author":"Hwang","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41598-017-01924-9","article-title":"Serum Metabolomic Profiles for Breast Cancer Diagnosis, Grading and Staging by Gas Chromatography-Mass Spectrometry","volume":"7","author":"Hadi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115774","DOI":"10.18632\/oncotarget.22404","article-title":"Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: Mini review","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cardoso, M.R., Santos, J.C., Ribeiro, M.L., Talarico, M.C.R., Viana, L.R., and Derchain, S.F.M. (2018). A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020617"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/bmm-2017-0449","article-title":"Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach","volume":"12","author":"Fujigaki","year":"2018","journal-title":"Biomark. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/gerona\/gly128","article-title":"Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival","volume":"74","author":"Huang","year":"2018","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-17-2855","article-title":"Prediction of Chemotherapeutic Efficacy in Non\u2013Small Cell Lung Cancer by Serum Metabolomic Profiling","volume":"24","author":"Tian","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/ijc.32218","article-title":"Prospective serum metabolomic profiling of lethal prostate cancer","volume":"145","author":"Huang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_22","first-page":"3491852","article-title":"Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by <sup>1<\/sup>H-NMR Spectrometry","volume":"2019","author":"Gu","year":"2019","journal-title":"Dis. Mark."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1021\/acs.jproteome.8b00803","article-title":"Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway\u2019s Metabolites in Humans with Prostate Cancer","volume":"18","author":"Khan","year":"2019","journal-title":"J. Proteome Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bjerrum, J.T. (2015). Metabonomics: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-4939-2377-9"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11306-017-1269-9","article-title":"Identification of putative biomarkers for leptomeningeal invasion in B-cell non-Hodgkin lymphoma by NMR metabolomics","volume":"13","author":"Desterro","year":"2017","journal-title":"Metabolomics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ijc.20651","article-title":"Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics","volume":"113","author":"Odunsi","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1021\/pr101050d","article-title":"Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe","volume":"10","author":"Garcia","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11306-017-1254-3","article-title":"Metabolomic characterization of experimental ovarian cancer ascitic fluid","volume":"13","author":"Bharti","year":"2017","journal-title":"Metabolomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4155\/bio.11.155","article-title":"Advances in metabolite identification","volume":"3","author":"Wishart","year":"2011","journal-title":"Bioanalysis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11306-007-0099-6","article-title":"Assessment of PLSDA cross validation","volume":"4","author":"Westerhuis","year":"2008","journal-title":"Metabolomics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"ref_32","first-page":"519","article-title":"Ovarian Cancer: Diagnostic, Biological and Prognostic Aspects","volume":"10","author":"Davidson","year":"2014","journal-title":"Women\u2019s Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: Exploiting cancer stem cell metabolism","volume":"29","author":"Li","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-34025-4_1","article-title":"Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders","volume":"Volume 1219","author":"Serpa","year":"2020","journal-title":"Tumor Microenvironment. Advances in Experimental Medicine and Biology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.yexcr.2013.02.017","article-title":"Metabolic changes during ovarian cancer progression as targets for sphingosine treatment","volume":"319","author":"Anderson","year":"2013","journal-title":"Exp. Cell Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.18632\/oncotarget.6891","article-title":"Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy","volume":"7","author":"Kyriakides","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1731::AID-CNCR20>3.0.CO;2-4","article-title":"1H-magnetic resonance spectroscopy","volume":"82","author":"Massuger","year":"1998","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11306-016-0990-0","article-title":"Metabolomics of biomarker discovery in ovarian cancer: A systematic review of the current literature","volume":"12","author":"Turkoglu","year":"2016","journal-title":"Metabolomics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000010258","article-title":"Significance of Serum and Peritoneal Fluid Lactate Dehydrogenase Levels in Ovarian Cancer","volume":"49","author":"Boran","year":"2000","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1525-1438.1996.06040328.x","article-title":"Serum lactate dehydrogenase levels in malignant germ cell tumors of ovary","volume":"6","author":"Patel","year":"1996","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/gyno.1997.4792","article-title":"Peritoneal Fluid Lactate Dehydrogenase in Ovarian Cancer","volume":"66","author":"Schneider","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"ref_42","first-page":"2788","article-title":"Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si-SA\u03a4B1 in ovarian cancer","volume":"40","author":"Xiang","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/0008-5472.CAN-15-2298","article-title":"Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas","volume":"76","author":"Hilvo","year":"2016","journal-title":"Cancer Res."},{"key":"ref_44","unstructured":"Dhillon, K.K., and Gupta, S. (2020). Biochemistry, Ketogenesis, StatPearls Publishing."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kim, J.T., Li, C., Weiss, H.L., Zhou, Y., Liu, C., Wang, Q., and Evers, B.M. (2019). Regulation of Ketogenic Enzyme HMGCS2 by Wnt\/\u03b2-catenin\/PPAR\u03b3 Pathway in Intestinal Cells. Cells, 8.","DOI":"10.3390\/cells8091106"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1021\/acs.jproteome.7b00503","article-title":"Metabolomic Signature of Endometrial Cancer","volume":"17","author":"Troisi","year":"2018","journal-title":"J. Proteome Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1158\/1078-0432.CCR-10-1434","article-title":"Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers","volume":"16","author":"Slupsky","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrc.2016.87","article-title":"The metabolic fate of acetate in cancer","volume":"16","author":"Schug","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41416-018-0270-z","article-title":"Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism","volume":"119","author":"Niemi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41419-019-1832-6","article-title":"Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer","volume":"10","author":"Shan","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.29010","article-title":"Large-scale profiling of metabolic dysregulation in ovarian cancer","volume":"136","author":"Ke","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Plewa, S., Hora\u0142a, A., Derezi\u0144ski, P., Klupczynska, A., Nowak-Markwitz, E., Matysiak, J., and Kokot, Z.J. (2017). Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122727"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lfs.2019.03.004","article-title":"Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers","volume":"222","author":"Plewa","year":"2019","journal-title":"Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/pr3009572","article-title":"Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling","volume":"12","author":"Zhang","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature26140","article-title":"The protein histidine phosphatase LHPP is a tumour suppressor","volume":"555","author":"Hindupur","year":"2018","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41586-018-0316-7","article-title":"Histidine catabolism is a major determinant of methotrexate sensitivity","volume":"559","author":"Kanarek","year":"2018","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fonc.2020.00947","article-title":"Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival","volume":"10","author":"Serpa","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1021\/pr200173q","article-title":"Serum 27-nor-5\u03b2-Cholestane-3,7,12,24,25 Pentol Glucuronide Discovered by Metabolomics as Potential Diagnostic Biomarker for Epithelium Ovarian Cancer","volume":"10","author":"Chen","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_60","first-page":"174019","article-title":"Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy","volume":"2011","author":"Sellem","year":"2011","journal-title":"J. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11306-018-1448-3","article-title":"Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: A pilot study","volume":"14","author":"Garg","year":"2018","journal-title":"Metabolomics"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zeleznik, O.A., Eliassen, A.H., Kraft, P., Poole, E.M., Rosner, B., Jeanfavre, S., Deik, A., Bullock, K., Hitchcock, D., and Avila-Pancheco, J. (2019). A prospective analysis of circulating plasma metabolomics and ovarian cancer risk. bioRxiv.","DOI":"10.1101\/654962"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"23334","DOI":"10.1038\/srep23334","article-title":"Metabolic phenotyping for monitoring ovarian cancer patients","volume":"6","author":"Ke","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1159\/000495492","article-title":"Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC\/Q-TOF MS","volume":"51","author":"Yang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2018.02.029","article-title":"Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer","volume":"481","author":"Kozar","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10795","DOI":"10.1158\/0008-5472.CAN-06-0755","article-title":"Mass Spectrometry\u2013Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors","volume":"66","author":"Denkert","year":"2006","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/9\/989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:01Z","timestamp":1760129101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/9\/989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["metabo13090989"],"URL":"https:\/\/doi.org\/10.3390\/metabo13090989","relation":{},"ISSN":["2218-1989"],"issn-type":[{"type":"electronic","value":"2218-1989"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}